Harenberg J, Baumgärtner A, Fritze D, Zimmermann R
Blut. 1982 Apr;44(4):241-7. doi: 10.1007/BF00319910.
The effect of an immunotherapy with Corynebacterium parvum on the blood coagulation system was investigated in a randomized trial of 18 patients with metastatic breast cancer. All patients received cytostatic therapy. Additionally, C. parvum was given intravenously on day 15 of the cytostatic cycle (group I) or on day 1 (group II) or not at all (group III). Fibrinopeptide A increased within 2 h after intravenous administration of C. parvum in groups I and II and normalized after 24 h (p less than 0.05). Platelet counts decreased continuously in all treatment groups (p less than 0.05). Prothrombin time, fibrinolytic concentration, factor VIII:C and factor VIIIR:Ag were not affected. The fibrinolytic activity showed a slight but not statistically significant increase after intravenous administration of C. parvum. The data suggest that plasma hypercoagulability is induced or enhanced in man even after small intravenous doses of C. parvum.
在一项针对18例转移性乳腺癌患者的随机试验中，研究了微小棒状杆菌免疫疗法对血液凝固系统的影响。所有患者均接受了细胞抑制疗法。此外，在细胞抑制周期的第15天（第一组）或第1天（第二组）静脉注射微小棒状杆菌，或根本不注射（第三组）。在第一组和第二组中，静脉注射微小棒状杆菌后2小时内纤维蛋白肽A增加，24小时后恢复正常（p小于0.05）。所有治疗组的血小板计数持续下降（p小于0.05）。凝血酶原时间、纤维蛋白溶解浓度、因子VIII:C和因子VIIIR:Ag均未受影响。静脉注射微小棒状杆菌后，纤维蛋白溶解活性有轻微增加，但无统计学意义。数据表明，即使静脉注射小剂量的微小棒状杆菌，也会在人体内诱导或增强血浆高凝状态。
